Close Menu

NEW YORK (GenomeWeb) – Quidel today reported preliminary revenues for the fourth quarter of 2015 well below analyst forecasts.

Due to a weak influenza season, the firm now expects Q4 revenues between $52 million and $53 million, below analysts' consensus estimate of $64 million.

Investors reacted negatively to the news, sending Quidel's shares down around 7 percent to $17.67 in mid-morning trade on the Nasdaq. The shares had fallen to as low as $16.71 earlier in the session.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.